Which drug is advised only for patients with stable heart failure?

The correct choice is SGLT2 inhibitors, which are advised for patients with stable heart failure primarily because they have been shown to provide significant benefits in this population. SGLT2 inhibitors, originally developed for the treatment of type 2 diabetes, have demonstrated effects beyond glycemic control. They have been associated with improved heart failure outcomes, including reduced hospitalizations for heart failure and cardiovascular mortality in patients with stable heart failure, regardless of whether they have diabetes.

This class of drugs works by promoting urine glucose excretion, leading to osmotic diuresis, which helps reduce fluid overload—a common concern in heart failure management. Additionally, they lower blood pressure and have a favorable effect on cardiac metabolism, making them particularly suitable for patients who are stable and managing chronic heart failure.

In contrast, ACE inhibitors are typically used in both stable and acute heart failure but do not have the specific indication of being used exclusively for stable heart failure. Digoxin, while used to improve heart function, particularly in patients with heart failure and atrial fibrillation, requires careful monitoring of plasma levels and is not exclusively recommended for stable patients. Nitrates are more commonly used in acute settings for angina and heart failure exacerbations rather than for stable heart failure management. Therefore